Charles River Laboratories International (CRL) Expected to Announce Earnings on Wednesday

Charles River Laboratories International (NYSE:CRL) is anticipated to announce its earnings results before the market opens on Wednesday, February 12th. Analysts expect the company to announce earnings of $2.51 per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. During the same period in the prior year, the firm posted $2.72 earnings per share. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. On average, analysts expect Charles River Laboratories International to post $10 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Charles River Laboratories International Stock Up 0.8 %

CRL opened at $162.95 on Wednesday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The company has a market capitalization of $8.33 billion, a PE ratio of 20.39, a P/E/G ratio of 6.25 and a beta of 1.37. The stock’s fifty day moving average is $182.67 and its 200-day moving average is $194.47. Charles River Laboratories International has a one year low of $159.65 and a one year high of $275.00.

Insiders Place Their Bets

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the sale, the director now owns 12,386 shares of the company’s stock, valued at $2,676,862.32. This trade represents a 34.83 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 1.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on CRL shares. Redburn Atlantic began coverage on shares of Charles River Laboratories International in a research report on Monday, October 14th. They issued a “sell” rating and a $151.00 price target on the stock. Evercore ISI boosted their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a report on Thursday, November 7th. William Blair lowered shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. JPMorgan Chase & Co. decreased their price target on shares of Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating on the stock in a research report on Monday. Finally, UBS Group reiterated a “neutral” rating and set a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Three equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $202.08.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).